138529-04-1

The increase of postprandial blood glucose levels are significantly suppressed in the Diphlorethohydroxycarmalol-administered group than those in the streptozotocin-induced diabetic or normal mice. Moreover, the area under curve (AUC) is significantly reduced via Diphlorethohydroxycarmalol (100 mg/kg; p.o.) administration (2022 versus 2210 mmol x min/lL) in the diabetic mice as well as it delays absorption of dietary carbohydrates^[1].